Трансплантация в онкологии – будущее мультидисциплинарного подхода

7 февраля 2019 г. состоялась однодневная консенсусная конференция Международного общества трансплантации печени, посвященная вопросам онкологии. В Роттердаме (Нидерланды) собрались представители ведущих мировых клиник. В течение одного дня были сделаны доклады о гепатоцеллюлярном раке, раке желчных протоков, иммунотерапии и ее месте в лечении опухолей печени, возможности трансплантации печени у пациентов с метастатическим заболеванием печени, мировых тенденциях в детской онкогепатологии. Для обсуждения наиболее резонансных вопросов в рабочих группах была выделена отдельная сессия. Встреча обозначила основные мировые тенденции и наиболее актуальные темы в вопросах трансплантации печени у пациентов с онкологическим диагнозом. Вероятно, именно эти доклады будут «задавать тон» большому трансплантологическому конгрессу в Торонто в мае 2019 г.

1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. PMID: 27733281 https://doi.org/10.1016/S0140-6736(16)31012-1

2. Saez-Gonzalez E, Vinaixa C, San Juan F, Hontangas V, Benlloch S, Aguilera V, et al. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). Liver Int. 2018;38(6):1022–1027. PMID: 29105320 https://doi.org/10.1111/liv.13618

3. Llovet JM. Liver cancer: time to evolve trial design after everolimus failure. Nat Rev Clin Oncol. 2014;11(9):506–507. PMID: 25091613 https://doi.org/10.1038/nrclinonc.2014.136

4. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–472. PMID: 26205340 https://doi.org/10.1038/nrc3973

5. Kudo M. Combination Cancer Immunotherapy in Hepatocellular Carcinoma. Liver Cancer. 2018;7(1):20–27. PMID: 29662830 https://doi.org/10.1159/000486487

6. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. PMID: 21374666 https://doi.org/10.1002/hep.24199

7. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968–1977. PMID: 25689978 https://doi.org/10.1002/hep.27752

8. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, et al. Excellent Outcomes of Liver Transplantation Following down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018;16(6):955–964. PMID: 29175528 https://doi.org/10.1016/j.cgh.2017.11.037

9. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4):986–994.e3; quiz e14–5. PMID: 22750200 https://doi.org/10.1053/j.gastro.2012.05.052

10. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64(6):2077–2088. PMID: 27178646 https://doi.org/10.1002/hep.28643

11. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20(8):945–951. PMID: 24797281 https://doi.org/10.1002/lt.23904

12. Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, et al. Recurrence after liver transplantation for HCC-a new MORAL to the story. Ann Surg. 2017;265(3):557-564. PMID: 27611615 https://doi.org/10.1097/SLA.0000000000001966

13. Takada Y, Kaido T, Shirabe K, Nagano H, Egawa H, Sugawara Y, et al. LTx- PET study group of the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Liver Transplantation Society. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. J Hepatobiliary Pancreat Sci. 2017;24(1):49–57. PMID: 27806426 https://doi.org/10.1002/jhbp.412

14. European Association for the Study of the Liver. Electronic address: easloffice@ easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. PMID: 29628281 https://doi.org/10.1016/j.jhep.2018.03.019

15. Llovet JM. Liver cancer: time to evolve trial design after everolimus failure. Nat Rev Clin Oncol. 2014;11(9):506–507. PMID: 25091613 https://doi.org/10.1038/nrclinonc.2014.136

16. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21(5):594–599. PMID: 27000463 https://doi.org/10.1634/theoncologist.2015-0446

17. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54(2):463–471. PMID: 21538440 https://doi.org/10.1002/hep.24397

18. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–1289. PMID: 24681130 https://doi.org/10.1016/j.jhep.2014.01.021

19. Sapisochin G, Rodriguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant. 2014;14(3):660–667. PMID: 24410861 https://doi.org/10.1111/ajt.12591

20. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25(12):2328–2338. PMID: 24769639 https://doi.org/10.1093/annonc/mdu162

21. Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, et al. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014;5(6):408–413. PMID: 25436118 https://doi.org/10.3978/j.issn.2078-6891.2014.072

22. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016;34(3):219–226. PMID: 26503201 https://doi.org/10.1200/JCO.2015.61.3778

23. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847. PMID: 27622582 https://doi.org/10.1002/ cncr.30254

24. Dang L, White DW, Gross S, Bennett BD, Ghobrial RM, Bittinger A, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. PMID: 19935646 https://doi.org/10.1038/nature08617

25. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282. PMID: 29182496 https://doi.org/10.1200/JCO.2017.75.5009

26. Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163(4):732–738. PMID: 29336813 https://doi.org/10.1016/j.surg.2017.08.011

27. Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg. 2018;267(5):797–805. PMID: 29064885 https://doi.org/10.1097/SLA.0000000000002574

28. Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, et al. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015;261(5):956–960. PMID: 24950280 https://doi.org/10.1097/SLA.0000000000000786

29. Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, et al. Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg. 2018;105(3):295–301. PMID: 29168565 https://doi.org/10.1002/bjs.10651

30. Grut H, Revheim ME, Line PD, Dueland S. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation. Nucl Med Commun. 2018;39(7):621–627. PMID: 29683930 https://doi.org/10.1097/MNM.0000000000000843

31. Line PD, Hagness M, Berstad AE, Foss A, Dueland S. A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases: The RAPID Concept. Ann Surg. 2015;262(1):e5–9. PMID: 25692361 https://doi.org/10.1097/SLA.0000000000001165

32. Czaudernaa P, Haeberleb B, Hiyamac E, Rangaswamid A, Ghobrial Krailoe RM, Maibachf R, et al. The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92–101. PMID: 26655560 https://doi.org/10.1016/j.ejca.2015.09.023

33. Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 2018;48(4):536–554. PMID: 29427028 https://doi.org/10.1007/s00247-018-4078-z

34. Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol. 2018;24(35):3980–3999. PMID: 30254403 https://doi.org/10.3748/wjg.v24.i35.3980